What is it about?
We used focused ultrasound in combination with a thermally sensitive drug carrier to demonstrate targeted drug delivery to liver tumours that had been resistant to other therapies.
Featured Image
Why is it important?
To our knowledge, this clinical study is the first to investigate the safety and feasibility of extracorporeally triggered drug release in oncology and to quantify the potential benefits of this approach in terms of the drug dose, distribution, and cellular delivery, in addition to radiologically assessing the observed therapeutic response induced by a single systemically administered course of chemotherapy.
Perspectives
Our study highlights the clinical potential of device-based drug delivery approaches in general, and ultrasound in particular, to achieve several-fold enhancements in the delivery and distribution of existing and future therapeutic agents to solid tumours, with potentially transformative implications for their therapeutic effectiveness at a given systemic dose.
Michael Gray
University of Oxford
Read the Original
This page is a summary of: Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial, The Lancet Oncology, July 2018, Elsevier,
DOI: 10.1016/s1470-2045(18)30332-2.
You can read the full text:
Contributors
The following have contributed to this page
